| Journal | The lancet. Psychiatry |
| Study Type | Randomized Trial |
| Population | Human participants |
This systematic review and meta-analysis represents the most comprehensive evaluation to date of randomized controlled trial evidence for cannabinoids treating mental health and substance use disorders. Given that psychiatric conditions are among the most common reasons patients seek cannabis treatment, establishing the evidence base is critical for clinical decision-making.
The authors conducted a systematic review and meta-analysis of randomized controlled trials evaluating cannabinoids as primary treatment for mental disorders and substance use disorders, searching major databases from 1980 to 2025. Primary outcomes focused on disorder remission or symptom reduction, with safety assessed through adverse event rates and number needed to treat to harm calculations. The study addresses a significant evidence gap, as mental health conditions represent leading indications for medical cannabis approval despite limited high-quality trial data. The methodology appears robust with dual independent review, though specific findings regarding efficacy and safety outcomes are not detailed in this summary.
โWhat this paper really shows is how careful we still need to be. The evidence is broad enough to sound reassuring at first glance, but underneath that are studies that are too mixed, too short, and too methodologically shaky to justify broad conclusions.โ
๐ฌ Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan โ
Want to discuss this topic with other patients and caregivers? Join the forum discussion โ
Have thoughts on this? Share it: